Home › Research › Topics › neurofilament
neurofilament
699 studies tagged neurofilament, dated 1989-01-01 to 2026-11-01. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Inflammatory biomarker candidates in dementia with Lewy bodies: diagnostic classification, clinical associations, and survival 2026-11-01
- Longitudinal plasma biomarkers and multimodal PET across APOE ε4 genotypes: a prospective cohort study 2026-11-01
- Concurrent cognitive, behavioral and systemic physiological features mark preclinical Alzheimer's disease 2026-10-30
Studies
699 studies carry this tag.
Date range
1989 to 2026
Top journals
- Alzheimer's & dementia : the journal of the Alzheimer's Association 123
- Journal of Alzheimer's disease : JAD 53
- Alzheimer's & dementia (Amsterdam, Netherlands) 46
- Alzheimer's research & therapy 36
- medRxiv 29
196 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
77/100
A total of 17 articles were identified. Plasma Aβ42/40 ratio was inversely correlated with aPET positivity r = -0.48 (95% confidence interval (CI): -0.65--0.31).
-
Blood biomarkers have been considered tools for the diagnosis, prognosis, and monitoring of Alzheimer's disease (AD).
-
Recently, low-sensitive plasma assays have been replaced by new ultra-sensitive assays such as single molecule enzyme-linked immunosorbent assay (Simoa), the Mesoscale Discovery (MSD) platform, and immunoprecipitation-mass spectrometry (IP-MS) with higher accuracy in the determination of plasma biomarkers of Alzheimer's disease (AD).
-
Plasma β-synuclein levels were higher in preclinical AD and even higher in MCI and AD dementia.
-
Blood phosphorylated tau (p-tau) biomarkers, at differing sites, demonstrate high accuracy to detect Alzheimer's disease (AD).
-
52/100
Plasma and CSF p-tau 217 had equivalent diagnostic performance for biomarker-defined AD.
-
Evaluating potential therapies for Alzheimer's disease (AD) depends on use of biomarkers for appropriate subject selection and monitoring disease progression.
-
Bisecting N-acetylglucosamine correlated with tau levels (p < 0.0001).
-
We examined whether plasma p-tau181 and p-tau217 are specific biomarkers of pathologically confirmed Alzheimer's disease (AD).
-
Plasma P-tau181 effectively detects Aβ+ status and conversion to dementia, confirming the value of this blood biomarker for the management of AD.
-
Blood-based tests have sparked tremendous attention in non-invasive early diagnosis of Alzheimer's disease (AD), a most prevalent neurodegenerative malady worldwide.
-
We aimed to assess the utility of AT(N) classification in clinical practice.
-
62/100
Plasma Aβ42/40 was a robust biomarker for AD which was not affected by renal function.
-
Cerebrospinal fluid (CSF) amyloid-β peptide (Aβ)42/Aβ40 and the concentration of tau phosphorylated at site 181 (p-tau181) are well-established biomarkers of Alzheimer's disease (AD).
-
67/100
Several promising plasma biomarkers for Alzheimer's disease have been recently developed, but their neuropathological correlates have not yet been fully determined.
-
High CSF p-tau235 levels were strongly associated with CSF amyloidosis regardless of the clinical diagnosis, being significantly increased in MCI Aβ+ and dementia Aβ+ when compared with all other Aβ- groups (Paris cohort: P ˂0.0001 for all; BIODEGMAR cohort: P ˂0.05 for all).
-
Alzheimer's disease (AD) associated proteins exist in cerebrospinal fluid (CSF).
-
Abnormal plasma Aβ42/40 ratio identified older adult groups with lower memory scores, higher dementia risks, and higher ADRD biomarker levels, with potential implications for population screening.
-
Twenty-nine participants' plasma p-tau181 samples were included (mean age 74 SD 8.5, 65% female).
-
62/100
Recent studies suggest that blood total-tau originates principally from peripheral, non-brain sources.
-
Emerging plasma biomarkers of Alzheimer's disease might be non-invasive tools to trace early Alzheimer's disease-related abnormalities such as the accumulation of amyloid-beta peptides, neurofibrillary tau tangles, glial activation and neurodegeneration.
-
Amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) amyloid beta (Aβ)42/phosphorylated tau (p-tau)181 showed excellent performance in differentiating autopsy-confirmed AD and predicting the risk of neuropathological changes in early and late clinical stages.
-
This study is the first to delineate the trajectories of plasma biomarkers throughout the Alzheimer's continuum in the Chinese population, providing important implications for future trials targeting plasma GFAP to facilitate AD prevention and treatment.
-
Neurodegenerative and inflammatory processes influence the clinical course of multiple sclerosis (MS).
-
An unmet need exists for reliable plasma biomarkers of amyloid pathology, in the clinical laboratory setting, to streamline diagnosis of Alzheimer's disease (AD).
-
For Aβ42/Aβ40, cutoffs across cohorts were <0.059 (BioFINDER), <0.057 (ADNI), and <0.058 (UCSF).
-
Biofluid markers of phosphorylated tau181 (p-tau181) are increasingly popular for the detection of early Alzheimer's pathologic changes.
-
Recent findings Plasma biomarkers have significantly improved our understanding of ADRD time-course, risk factors, diagnosis and prognosis.
-
Plasma AB42/40 had the highest AUC (0.833, 95% C.I. 0.767-0.899) at a cut-point of 0.0706 for discriminating between the two cerebral amyloid groups (sensitivity 76%, specificity 78.5%).
-
Amyloid and tau biomarkers for Alzheimer's disease are widely recognized diagnostic tools for the identification of Alzheimer's disease pathology antemortem and are recommended by the most recent clinical and research guidelines.
-
The increasing prevalence of Alzheimer's disease (AD) has led to a health crisis.
-
Our findings support a role for plasma GFAP as a clinical biomarker of Aβ-related astrocyte reactivity that is associated with cognitive decline and neurodegeneration.
-
Deamidation products of blood albumin were significantly elevated in vascular dementia and frontotemporal dementia (P < 0.05), but less so in PD.
-
Carriers had higher plasma p-tau217 levels than non-carriers.
-
Alzheimer's disease (AD) is a neurological condition that affects millions of individuals around the world and for which there are few effective therapies.
-
55/100
TDP-43 was significantly elevated in plasma ADEVs derived from autopsy confirmed LATE-NC subjects, with or without comorbid AD pathology.
-
The median Aβ1-42/1-40 ratio was 20.86% lower in amyloid-positive subjects than in the amyloid-negative group, while the median AβX-42/X-40 ratio was only 15.56% lower.
-
(N = 558, mean age = 69.2 ± 8.8, 56.5% women) were diagnosed with AD (n = 274, considering dementia and MCI stages), frontotemporal dementia (FTD, n = 55), Lewy body disease (LBD, n = 40, considering MCI and dementia stages), other neurodegenerative diseases, n = 57 (e.g Supranuclear Palsy, Corticobasal syndrome), non-neurodegenerative cognitive impairment (NND, n = 79, e.g. vascular lesions, epilepsy or psychiatric disorders) or subjective cognitive impairment (SCI, n = 53).
-
Synaptic degeneration is an early event closely associated with the course of Alzheimer's disease (AD).
-
Idiopathic normal pressure hydrocephalus (iNPH) is a neurological syndrome characterized by the clinical triad of gait disorder, cognitive impairment and urinary incontinence.
-
Robust and accessible biomarkers that can capture the heterogeneity of Alzheimer's disease and its diverse pathological processes are urgently needed.
-
72/100
This fully-automated and available blood-based biomarker assay therefore may be useful for early detection, diagnosis, prognosis, and treatment monitoring of AD.
-
Several plasma p-tau biomarkers can be used in a specialized memory clinic as a stand-alone biomarker to detect biologically-defined AD.
-
59/100
Early identification of cognitive impairment in Parkinson’s disease (PD) has important clinical and research implications.
-
Of 349 participants with available plasma data, 234 met inclusion criteria (31 controls, 141 in the training sample, and 62 in the validation sample).
-
Blood exosomes, which are extracellular vesicles secreted by living cells into the circulating blood, are regarded as a relatively noninvasive novel tool for monitoring brain physiology and disease states.
-
The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials.
-
Both plasma and CSF measures of Aβ42/Aβ40 and NfL predicted cognitive decline.
-
Movement disorders have been carefully clinically defined, based on clinico-pathological series; however there is often diagnostic and prognostic uncertainty, especially in early stage disease.
-
Among participants enrolled, the median (interquartile range) age was 57 (28.5-75) years and 5.8% had AD.
From across this tag
9 of the 697 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- How Comorbidity Reflects on Cerebrospinal Fluid Biomarkers of Neurodegeneration in Aging
- Plasma transthyretin as a candidate marker for Alzheimer's disease
- A Decade of Protecting Progress: Ethics Review
- Genetic risk and plasma biomarkers of dementia with Lewy bodies in a Chinese population
- Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
- Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer's disease
- Clinical expression beyond measured Alzheimer disease molecular pathology: a discovery and external evaluation study
- Clinical Application of Plasma Neurofilament Light Chain in a Memory Clinic: A Pilot Study
- Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease